Mesoblast (MEOBF) Total Non-Current Liabilities (2015 - 2026)
Mesoblast's (MEOBF) quarterly Total Non-Current Liabilities came in at $123.6 million in Q2 2026, up 46.03% year-over-year from $84.6 million in Q2 2025, and up 55.32% quarter-over-quarter from $79.6 million in Q4 2025.
Analysis
Mesoblast (MEOBF) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Mesoblast has disclosed Total Non-Current Liabilities across 12 years of filings, most recently posting $123.6 million for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 46.03% year-over-year to $123.6 million; the TTM figure through Jun 2026 stood at $123.6 million (up 46.03% YoY), while the FY2026 annual figure was $123.6 million, up 46.03% from the prior year.
- Total Non-Current Liabilities came in at $123.6 million for Q2 2026 at Mesoblast, up from $79.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $123.6 million in Q2 2026 to a low of $8.2 million in Q1 2023.
- Average Total Non-Current Liabilities over 5 years is $41.7 million, with a median of $14.9 million recorded in 2022.
- Year-over-year, Total Non-Current Liabilities slumped 91.89% in 2022 and soared 651.86% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $9.0 million in 2022, then jumped by 89.74% to $17.1 million in 2023, then plunged by 38.02% to $10.6 million in 2024, then soared by 651.86% to $79.6 million in 2025, then soared by 55.32% to $123.6 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $123.6 million in Q2 2026, $79.6 million in Q4 2025, and $84.6 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 134.44 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 898.00 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 72.64 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 117.70 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 577.71 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 313.33 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 126.64 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 1.66 Bn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 130.91 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | 123.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 123.56 Mn |
| Dec 31, 2025 | 79.55 Mn |
| Jun 30, 2025 | 84.62 Mn |
| Dec 31, 2024 | 10.58 Mn |
| Jun 30, 2024 | 115.56 Mn |
| Dec 31, 2023 | 17.07 Mn |
| Jun 30, 2023 | 16.61 Mn |
| Mar 31, 2023 | 8.17 Mn |
| Dec 31, 2022 | 9.00 Mn |
| Sep 30, 2022 | 9.85 Mn |
| Jun 30, 2022 | 12.52 Mn |
| Mar 31, 2022 | 13.18 Mn |
| Dec 31, 2021 | 110.98 Mn |
| Sep 30, 2021 | 69.17 Mn |
| Jun 30, 2021 | 17.02 Mn |
| Mar 31, 2021 | 17.82 Mn |
| Dec 31, 2020 | 19.44 Mn |
| Sep 30, 2020 | 20.72 Mn |
| Jun 30, 2020 | 27.56 Mn |
| Mar 31, 2020 | 28.11 Mn |